



Life Sciences

2016: Recognized both globally and nationally for its leading life sciences practice, WilmerHale has more than four decades of experience representing biotechnology, pharmaceutical and medical device companies at all stages of growth, as well as venture capitalists and investment banks. We have represented life sciences clients in venture financings, public offerings, mergers and acquisitions, and licensing agreements and collaborations; protected their innovations through patent prosecution and portfolio development; defended their interests in enterprise-critical patent litigation; and navigated regulatory issues vital to their success. The following is a selection of our recent life sciences transactions.

Counsel of Choice to Life Sciences Innovators

SERVING INDUSTRY LEADERS IN BIOTECHNOLOGY, PHARMACEUTICALS, MEDICAL DEVICES AND BEYOND



Mergers and Acquisitions/Strategic Alliances and Collaborations

 Acquisition by Merck \$510,000,000 (including contingent payments) July 2015	 Acquisition by Integra LifeSciences \$312,000,000 July 2015	 Sale of global portfolio of hemostasis products to Mallinckrodt \$410,000,000 (including contingent payments) February 2016	 Acquisition of Alfa Aesar research chemicals business of Johnson Matthey £256,000,000 September 2015	
 Collaboration with Sanofi for the development and commercialization of sotagliflozin	 Cancer immunotherapy collaboration with Juno Therapeutics	 Microbiome pharmaceutical licensing advice	 Hepatitis C collaboration with Janssen Pharmaceuticals	 Collaboration with Roche for the development of a TLR inhibitor

Initial Public Offerings

 Initial Public and Follow-on Offerings of Common Stock \$344,879,500 Counsel to Issuer February 2015 and December 2015	 Initial Public Offering of American Depositary Shares representing Ordinary Shares \$191,250,000 Counsel to Underwriters May 2015	 Initial Public Offering of Common Stock \$108,560,000 Counsel to Issuer February 2016	 Initial Public Offering of American Depositary Shares representing Ordinary Shares \$39,278,250 Counsel to Issuer March 2015	
 Initial Public Offering of Common Stock \$155,250,000 Counsel to Issuer July 2015	 Initial Public Offering of Common Stock \$60,000,000 Counsel to Issuer February 2015	 Initial Public Offering of Common Stock \$69,000,000 Counsel to Issuer June 2015	 Initial Public Offering of American Depositary Shares representing Shares \$64,400,000 Counsel to Underwriters June 2015	 Initial Public Offering of American Depositary Shares representing Common Shares \$106,087,500 Counsel to Issuer September 2015

Venture Capital Financings

 \$55,000,000 Late Stage December 2015	 \$34,000,000 Fourth Round August 2015	 \$28,000,000 Fourth Round April 2015	 \$40,000,000 Late Stage January 2016	 \$47,000,000 Fourth Round December 2015
 \$217,000,000 First Round May 2015	 \$31,500,000 Late Stage June 2015	 \$90,000,000 Second Round December 2015	 \$40,000,000 Fourth Round June 2015	

Follow-on Offerings

 Public Offering of Common Stock \$86,250,000 Counsel to Issuer February 2015	 Public Offering of Common Stock \$149,988,750 Counsel to Underwriters July 2015	 Public Offering of Common Stock \$141,450,000 Counsel to Issuer February 2015	 Public Offering of Common Stock \$173,075,000 Counsel to Issuer March 2015	 Rule 144A Placement of 3.00% Convertible Senior Notes \$150,000,000 Counsel to Issuer August 2015
 Public Offerings of Common Stock \$569,718,750 Counsel to Issuer February 2015 and April 2015	 Public Offering of Common Stock \$101,200,000 Counsel to Issuer June 2015	 Public Offerings of Common Stock \$149,000,000 Counsel to Issuer January 2015 and December 2015	 Public Offerings of Common Stock \$262,500,000 Counsel to Issuer March 2015 and January 2016	



Mixed Sources
 Product group from well-managed forests, controlled sources and recycled wood or fiber
www.fsc.org Cert no. BV-COC-070904
 © 1996 Forest Stewardship Council

16_0216 KW 4/16 3000

WilmerHale recognizes its corporate responsibility to environmental stewardship.

Connect with us



wilmerhale.com

Wilmer Cutler Pickering Hale and Dorr LLP is a Delaware limited liability partnership. WilmerHale principal law offices: 60 State Street, Boston, Massachusetts 02109, +1 617 526 6000; 1875 Pennsylvania Avenue, NW, Washington, DC 20006, +1 202 663 6000. Our United Kingdom office is operated under a separate Delaware limited liability partnership of solicitors and registered foreign lawyers authorized and regulated by the Solicitors Regulation Authority (SRA No. 287488). Our professional rules can be found at www.sra.org.uk/solicitors/code-of-conduct.page. A list of partners and their professional qualifications is available for inspection at our UK office. In Beijing, we are registered to operate as a Foreign Law Firm Representative Office. This material is for general informational purposes only and does not represent our advice as to any particular set of facts; nor does it represent any undertaking to keep recipients advised of all legal developments. Prior results do not guarantee a similar outcome. © 2016 Wilmer Cutler Pickering Hale and Dorr LLP